$179 Million is the total value of CARNEGIE MELLON UNIVERSITY's 6 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Sell | DUOLINGO INC | $51,760,000 | -1.8% | 543,523 | -9.7% | 28.84% | +8.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES INC | 8 | Q3 2023 | 79.8% |
| DUOLINGO INC | 8 | Q3 2023 | 77.3% |
| NEUBASE THERAPEUTICS INC. | 8 | Q3 2023 | 1.1% |
| VERA THERAPEUTICS INC. | 8 | Q3 2023 | 0.4% |
| PREDICTIVE ONCOLOGY INC. | 8 | Q3 2023 | 0.1% |
| INNSUITES HOSPITALITY TRUST | 8 | Q3 2023 | 0.0% |
| CARMELL THERAPEUTICS CORP | 1 | Q3 2023 | 0.5% |
View CARNEGIE MELLON UNIVERSITY's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| NeuBase Therapeutics, Inc. | July 22, 2019 | 939,412 | 5.5% |
View CARNEGIE MELLON UNIVERSITY's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| 13F-HR | 2024-02-02 |
| 13F-HR | 2023-11-01 |
| 13F-HR | 2023-08-01 |
| 13F-HR | 2023-05-03 |
| 13F-HR | 2023-02-07 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-05 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View CARNEGIE MELLON UNIVERSITY's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.